STUDY OF POTENTIAL NEW DRUG COMBINATIONS FOR TREATMENT OF RESISTANT LEUKEMIA CASES

Sergej Charkavliuk1, Veronika Borutinskaitė1

1 Department of Molecular Cell Biology, Institute of Biochemistry, Life Science Center, Vilnius University, Lithuania

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy of the myeloid bloodline. The risk of developing this tumor grows over the years, whereas the efficiency of the conventional treatment drastically drops. Patients over 20 years of age have a 68% chance of surviving within 5 years, compared with just 26% for patients over 20 years of age. The unacceptable rates of survival are the results of high adaptation rates to standard treatment. More than 60% of elderly patients failed to induce chemotherapy owing to recurrence, and over 85% of patients failed in treatment [1].

Like so, there is a need for the development of new strategies with new or already existing drugs and their combination for patients with chemoresistance cases.

All malignant tumors share the consistent characteristic – avoidance of an apoptotic mechanism. In a number of leukemia types, the anti-apoptotic protein MCL1 is significantly higher compared to other proteins of the corresponding class. As follows, the way to the novel treatment of the patients may lay through the inhibition of the MCL1 proteins. The merge of the S63845 inhibitor, a BH3 mimetic, allowed to target these proteins in the cytoplasm. Both in vivo and in vitro studies showed a potential anti-cancer effect of S63845 on the number of MCL1 dependent leukemias and lymphomas cells. It was shown that S63845 caused poly ADP-ribose polymerase (PARP) breakage, exposure with caspase-dependent phosphatidyl-serine, and release of the mitochondrial cytochrome C. This indicates that S63845 affects cancer cells by directly inhibiting MCL1 and activating the BAX/BAK-dependent mitochondrial apoptotic pathway [2]. Although, there are not enough evidence to suggest the potential use of the novel inhibitor in the treatment of real patients. The therapeutical mechanism and the clinical effects of the S63845 require more research, which is jet to be conducted.

The aim of our study was to investigate the anti-proliferative and apoptotic effect of MCL1 inhibitor S63845 alone or in combination with conventional chemotherapy (Cytarabine, Idarubicin) on leukemia cells. KG-1a, the stem-like AML cell line was chosen as a model system for our study. We demonstrated that the S65845 alone at 100 nM concentration had no impact on the proliferation and viability of the KG1a cells during 96-hour treatment. Although, the combination of S65845 with 8 nM of Idarubicin caused a double effect on the viability, rather the 8 nM of Idarubicin or S65845 alone after 96-hour of treatment but has no impact on the proliferation. The combination of the S65845 with conventional treatment (Cytarabine 30nM and Idarubicin 8 nM) inhibited the growth of cells (70%) and viability compared to control cells after the 96 h of treatment. Expression changes of anti-, pro-apoptotic, oncogenes were detected by real-time –PCR analysis. We observed up-regulation of anti-apoptotic genes like BCL2L1, BCL2, BCL2A1, after combined treatment (S65845, Idarubicin, Cytarabine) at 24h point. Moreover, pro-apoptotic gene (BAX, PT53, BAK, APAF1) expression was up-regulated after 24 hours of combined treatment, however, mightier changes were observed after 96 h treatment. Also, changes in the expression of genes responsible for drug resistance (ABCB1), oncogenes, genes critical in epigenetic regulation (HDAC, DNMT), and stemness (NOTCH1, Lin28A) were observed.

In conclusion, these results suggest the combination of MCL1 inhibitor S63845 with conventional chemotherapy leads to growth inhibition in KG1a cells.


[1] Zhang, J., Gu, Y. and Chen, B., 2019. Mechanisms of drug resistance in acute myeloid leukemia. OncoTargets and Therapy, [online] Volume 12, pp.1937-1945. Available at: <https://doi.org/10.2147/OTT.S191621> [Accessed 6 October 2020].

[2] Kotschy, A., 2016. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 538(7626), pp.477–482.